Effects of Omega 3 in Hemodialysis Patients

This study has been completed.
Sponsor:
Information provided by:
Laboratoire Régional de Nutrition Humaine
ClinicalTrials.gov Identifier:
NCT00431899
First received: February 3, 2007
Last updated: NA
Last verified: February 2007
History: No changes posted
  Purpose

The aim of the study was to determine the effects of a 3-week fish oil oral supplementation on the metabolic fate and thermogenic effect of an oral glucose load in hemodialysis patients.


Condition Intervention
Hemodialysis
End Stage Renal Disease
Behavioral: fish oil supplementation

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Screening
Official Title: Effets of Fish Oil on Metabolic Fate of an Oral Glucose Load in Patients With End Stage Renal Disease Undergoing Hemodialysis

Resource links provided by NLM:


Further study details as provided by Laboratoire Régional de Nutrition Humaine:

Primary Outcome Measures:
  • plasma glucose utilization
  • glucose-induced thermogenesis

Estimated Enrollment: 8
Study Start Date: May 2003
Estimated Study Completion Date: November 2003
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • hemodialysis at least 6 months duration end stage renal disease

Exclusion Criteria:

  • - Age < 18 y ou > 75 y
  • Hemodialysis < 6 months
  • Diabetes, obesity
  • allergy to fish
  • Asthma
  • glucocorticoïds, propranolol,, Immunosuppressive drugs, Insulin, Somatostatin
  • erythropoïetin < 3 months
  • Cancer
  • Hemoglobin < 11 g/l
  • disease < 1 month
  • pregnancy
  • respiratory insufficiency
  • intensive sport practice
  • refusal
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00431899

Locations
France
Laboratoire Régional de Nutrition Humaine
Brest, 29, France, F-29200
Sponsors and Collaborators
Laboratoire Régional de Nutrition Humaine
Investigators
Principal Investigator: Jacques Delarue, MD,PhD CHU Cavale Blanche F-29200 Brest
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00431899     History of Changes
Other Study ID Numbers: HDW3
Study First Received: February 3, 2007
Last Updated: February 3, 2007
Health Authority: France: Ministry of Health

Keywords provided by Laboratoire Régional de Nutrition Humaine:
nutrition
omega 3 fatty acids
insulin resistance

Additional relevant MeSH terms:
Kidney Diseases
Kidney Failure, Chronic
Renal Insufficiency
Renal Insufficiency, Chronic
Urologic Diseases

ClinicalTrials.gov processed this record on October 21, 2014